Nick

Dr. Pulliam is a Scientific Lead, Translational Oncology, at Loxo Oncology at Lilly. His current work is focused on understanding mechanisms of resistance and therapeutic vulnerabilities in cancer. He was previously a medical writer for Eli Lilly and Company, supporting their oncology platform, with a focus on breast cancer drug development. In this role, he supported nearly 30 manuscripts and many abstracts for presentation at cancer focused conferences. This expertise in cancer biology is further exemplified by authored publications in well-respected journals such as: Clinical Cancer Research, Molecular and Cellular Research, Oncogene, and Breast Cancer, as well as a written book chapter in Springer: Cancer Drug Discovery and Development.

Currently, Pulliam is host to “Science 101” – a medium centered on simplifying and sharing science with anyone interested. Prior to his work at Eli Lilly and Company, Pulliam completed his PhD in molecular biochemistry with a focus on epigenetic therapies (DNMT1 inhibitors) and DNA damaging agents (PARP inhibitors) in breast and ovarian cancer. Briefly, we demonstrated guadecitabine (DNMT inhibitor) increased intracellular ROS promoting PARP activation in PKA-dependent manner, and ultimately PARP inhibitor sensitivity. Importantly, the outcome of this study, which involved collaboration with several pharmaceutical companies, resulting in preparation of a clinical trial in triple negative breast cancer patients.